Restart Life Sciences Corp.
HEAL
CNSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 133.37% | 42.72% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 132.50% | 42.60% | |||
| Operating Income | -132.50% | -42.60% | |||
| Income Before Tax | -99.97% | 608.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -99.97% | 608.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -99.97% | 608.91% | |||
| EBIT | -132.50% | -42.60% | |||
| EBITDA | -133.37% | -42.72% | |||
| EPS Basic | -100.00% | 604.44% | |||
| Normalized Basic EPS | -122.22% | -28.57% | |||
| EPS Diluted | -138.10% | 426.67% | |||
| Normalized Diluted EPS | -111.76% | -21.43% | |||
| Average Basic Shares Outstanding | 12.42% | 0.17% | |||
| Average Diluted Shares Outstanding | 20.73% | 3.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||